Genentech Presses For Cancer Drug Patent's Invalidation
Genentech Inc. urged a California federal judge on Thursday to invalidate a patent at the center of Phigenix Inc.'s infringement suit targeting Genetech's breast cancer treatment Kadcyla, arguing the patent's claims...To view the full article, register now.
Already a subscriber? Click here to view full article